keyword
MENU ▼
Read by QxMD icon Read
search

docetaxel outcome

keyword
https://www.readbyqxmd.com/read/28105156/establishment-of-a-first-line-second-line-treatment-model-for-human-pulmonary-adenocarcinoma
#1
Lining Wang, Yu Wang, Qi Guan, Yong Liu, Tianyi He, Jiaru Wang
Lung cancer is one of the most prevalent types of cancer in the world. Surgery, chemotherapy and radiotherapy are used clinically as treatments for numerous cancers. Due to the appearance of drug resistance, the remission rate is limited to 40-50%. Docetaxel and pemetrexed are two drugs commonly used, and their effects in single-phase cell culture are well known. From the pharmacological point of view, it appears rational to hypothesize that sequential therapy effects can show better outcomes compared with traditional single-phase experiments...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28095710/the-evolving-role-of-chemotherapy-in-prostate-cancer
#2
Suliman Boulos, Danish Mazhar
Despite extensive clinical research of different chemotherapy agents for more than three decades, the role of chemotherapy in prostate cancer was only established in 2004, after demonstrating a survival benefit with docetaxel in metastatic castration-resistant prostate cancer. 6 years later, second-line chemotherapy using cabazitaxel, after disease progression on docetaxel, demonstrated an additional survival improvement. Recently, docetaxel given alongside standard hormonal therapy in newly diagnosed advanced prostate cancer was found to lead to significantly improved patient outcomes...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28081304/comparison-of-an-ac-taxane-versus-ac-free-regimen-and-paclitaxel-versus-docetaxel-in-patients-with-lymph-node-positive-breast-cancer-final-results-of-the-national-surgical-adjuvant-study-of-breast-cancer-02-trial-a-randomized-comparative-phase-3-study
#3
Toru Watanabe, Masaru Kuranami, Kenichi Inoue, Norikazu Masuda, Kenjiro Aogi, Shinji Ohno, Hiroji Iwata, Hirofumi Mukai, Yukari Uemura, Yasuo Ohashi
BACKGROUND: In postoperative patients with breast cancer, the combination of an anthracycline and cyclophosphamide (AC) followed by a taxane is a standard regimen. In the current study, the authors examined whether AC could be safely omitted, and compared the effectiveness of paclitaxel versus docetaxel. METHODS: Female postoperative patients with axillary lymph node-positive breast cancer were eligible for enrollment in this phase 3, open-label, randomized controlled trial at 84 centers in Japan...
January 12, 2017: Cancer
https://www.readbyqxmd.com/read/28068151/prognostic-impact-of-pretreatment-neutrophil-to-lymphocyte-ratio-in-castration-resistant-prostate-cancer-patients-treated-with-first-line-docetaxel
#4
Consuelo Buttigliero, Chiara Pisano, Marcello Tucci, Francesca Vignani, Valentina Bertaglia, Davide Iaconis, Pamela Guglielmini, Gianmauro Numico, Giorgio V Scagliotti, Massimo Di Maio
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, has been associated with poor outcome in several solid tumors, including prostate cancer. We retrospectively investigated the prognostic role of pretreatment NLR in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel. METHODS: All CRPC patients treated with first-line docetaxel at two Italian institutions, with available data about baseline neutrophil and lymphocyte values, were included in this retrospective analysis...
January 9, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28062933/single-cycle-induction-chemotherapy-for-resectable-advanced-hypopharyngeal-cancer
#5
Torahiko Nakashima, Ryuji Yasumatsu, Kaori Asai, Hideoki Uryu, Ryunosuke Kogo, Takashi Nakagawa
BACKGROUND: The role of induction chemotherapy (IC) in the treatment of resectable advanced head and neck squamous cell carcinoma has not been elucidated, and the most effective IC regimen for chemoselection is still unknown. At our institute we have not used the triple combination of docetaxel, cisplatin, fluorouracil (TPF) for chemoselection, but rather the double combination of docetaxel + cisplatin (TP). The aim of this study is to report the outcome of patients with advanced hypopharyngeal cancer treated by single cycle of IC with TP followed by chemoradiation (CRT) or surgery...
January 6, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28055108/impact-of-ethnicity-on-the-outcome-of-men-with-metastatic-hormone-sensitive-prostate-cancer
#6
Brandon Bernard, Vinayak Muralidhar, Yu-Hui Chen, Srikala S Sridhar, Edith P Mitchell, Curtis A Pettaway, Michael A Carducci, Paul L Nguyen, Christopher J Sweeney
BACKGROUND: Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races. METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race...
January 5, 2017: Cancer
https://www.readbyqxmd.com/read/28050147/sensor-controlled-scalp-cooling-to-prevent-chemotherapy-induced-alopecia-in-female-cancer-patients
#7
M K Fehr, J Welter, W Sell, R Jung, R Felberbaum
BACKGROUND: Scalp cooling has been used since the 1970s to prevent chemotherapy-induced alopecia, one of the most common and psychologically troubling side effects of chemotherapy. Currently available scalp cooling systems demonstrate varying results in terms of effectiveness and tolerability. METHODS: For the present prospective study, 55 women receiving neoadjuvant, adjuvant, or palliative chemotherapy were enrolled. The aim was to assess the effectiveness of a sensor-controlled scalp cooling system (DigniCap: Sysmex Europe GmbH, Norderstedt, Germany) to prevent chemotherapy-induced alopecia in breast or gynecologic cancer patients receiving 1 of 7 regimens...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28045610/evolving-treatment-of-oligometastatic-hormone-sensitive-prostate-cancer
#8
Jessica M Clement, Christopher J Sweeney
Oligometastatic disease was postulated by Hellman and Weichselbaum in 1995 to be a disease state that may reflect a time point in the malignant process that may be amenable to local therapies to allow for patients to achieve a durable response or possible cure despite having advanced disease. Aggressive metastasis-directed therapy has been used in malignancies such as renal cell carcinoma, non-small-cell lung cancer, and colorectal cancer with some evidence of long-term benefit in selected patients. Recently, it has been proposed that some men with oligometastatic hormone-sensitive prostate cancer may also benefit from metastasis-directed therapy...
January 3, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28036270/induction-chemotherapy-for-the-treatment-of-non-endemic-locally-advanced-nasopharyngeal-carcinoma
#9
Lina Zhao, Man Xu, Wen Jiang, Haitao Pan, Jian Zang, Shanquan Luo, Jianhua Wang, Yongchun Zhou, Mei Shi
BACKGROUND: The role of induction chemotherapy is less clear in non-endemic locally advanced nanopharyngeal carcinomas (NPC). RESULTS: With a total of 233 eligible patients and a median follow-up of 36 months, 3-year overall survival (OS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease free survival (DFS) were 84.5%, 94.9%, 78.6% and 69.2%, respectively. The overall failure rate was 21.0% and distant metastasis occurred in 17...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/28008196/clinical-characteristics-of-primary-peritoneal-carcinoma-patients-a-single-institution-experience-involving-8-patients
#10
Satomi Hattori, Hiroaki Kajiyama, Utako Fuji, Yuko Furui, Yuki Ishibashi, Yuka Hattori, Noriko Takahashi, Fumitaka Kikkawa, Toshiya Misawa
Primary peritoneal carcinoma (PPC) is treated similarly to advanced epithelial ovarian carcinoma (aEOC); however, the standard approach for the management of PPC is controversial. The objective of this study was to evaluate the clinical features and prognosis of those patients. A retrospective analysis was performed of eight patients with PPC between January 2008 and December 2015. Clinicopathologic parameters, the diagnostic modality, treatment, and oncologic outcome were analyzed. The median age at the time of diagnosis was 72...
December 2016: Nagoya Journal of Medical Science
https://www.readbyqxmd.com/read/28001301/tumor-response-to-neoadjuvant-chemotherapy-predicts-long-term-survival-outcomes-in-patients-with-locoregionally-advanced-nasopharyngeal-carcinoma-a-secondary-analysis-of-a-randomized-phase-3-clinical-trial
#11
Hao Peng, Lei Chen, Wen-Fei Li, Rui Guo, Yan-Ping Mao, Yuan Zhang, Ying Guo, Ying Sun, Jun Ma
BACKGROUND: Tumor response to neoadjuvant chemotherapy using the regimen of cisplatin and 5-fluorouracil could define high-risk patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, the regimen of docetaxel, cisplatin, and 5-fluorouracil (TPF) appears to be more effective than the regimen of cisplatin and 5-fluorouracil. Therefore, one needs to redefine the high-risk subpopulation of patients receiving neoadjuvant chemotherapy with TPF. METHODS: A total of 231 patients from a randomized phase 3 trial with American Joint Committee on Cancer/International Union Against Cancer stage III to stage IVB NPC (except T3-T4N0 disease) who were receiving treatment with the TPF regimen were enrolled...
December 21, 2016: Cancer
https://www.readbyqxmd.com/read/27995989/pharmacogenetic-variants-associated-with-outcome-in-patients-with-advanced-gastric-cancer-treated-with-fluoropyrimidine-and-platinum-based-triplet-combinations-a-pooled-analysis-of-three-prospective-studies
#12
D Meulendijks, E A Rozeman, A Cats, K Sikorska, M Joerger, M J Deenen, J H Beijnen, J H M Schellens
The main treatment for advanced gastric cancer is fluoropyrimidine and platinum-based chemotherapy. We investigated the clinical validitiy of 19 candidate pharmacogenetic variants in ENOSF1 (enolase superfamily member 1), TYMS, CDA, MTHFR, TYMP, DPYD, ERCC1, ERCC2, GSTP1, GSTT1, GSTM1, CYP3A4 and CYP3A5 in relation to overall survival (OS), progression-free survival, objective response rate (ORR) and toxicity in 185 patients receiving triplet chemotherapy. The formal significance threshold was P<0.0026. TYMS VNTR (variable number of 28-bp tandem repeats) 3 R/3 R genotype was formally associated with inferior ORR (odds ratio (OR) 0...
December 20, 2016: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/27979514/re-clinical-outcomes-in-octogenarians-treated-with-docetaxel-as-first-line-chemotherapy-for-castration-resistant-prostate-cancer
#13
Tomas L Griebling
No abstract text is available yet for this article.
January 2017: Journal of Urology
https://www.readbyqxmd.com/read/27977598/egfr-tkis-versus-taxanes-agents-in-therapy-for-nonsmall-cell-lung-cancer-patients-a-prisma-compliant-systematic-review-with-meta-analysis-and-meta-regression
#14
Na An, Yingshi Zhang, Huibin Niu, Zuojing Li, Jiayi Cai, Qingchun Zhao, Qing Li
BACKGROUND: Currently, the nonsmall-cell lung cancer (NSCLC) is a worldwide disease, which has very poor influence on life quality, whereas the therapeutic effects of drugs for it are not satisfactory. The aim of our PRISMA-compliant systematic review and meta-analysis was to compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with Taxanes in patients with lung tumors. METHODS: We collected randomized controlled trials (RCTs) of EGFR-TKIs (gefitinib, erlotinib) versus Taxanes (docetaxel, paclitaxel) for the treatment of NSCLC by searching PubMed, EMbase, and the Cochrane library databases until April, 2016...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27968861/effects-of-induction-taxotere-platinum-and-fluorouracil-tpf-chemotherapy-in-patients-with-stage-iii-and-iva-b-nasopharyngeal-cancer-treated-with-concurrent-chemoradiation-therapy-final-results-of-two-parallel-phase-2-clinical-trials
#15
Lin Kong, Youwang Zhang, Chaosu Hu, Ye Guo, Jiade J Lu
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced nasopharyngeal cancer. The effect of induction chemotherapy plus CCRT in patients with this stage of disease is unclear. We therefore examined the long-term outcomes of the addition of induction chemotherapy (consisting of docetaxel, cisplatin, and fluorouracil [TPF]) to CCRT in patients with stage III and IVA/B nasopharyngeal cancer. METHODS: Between January, 2007, and July, 2011, we synchronously undertook two parallel phase 2 single-arm trials to evaluate the efficacy and toxicity of TPF-based induction chemotherapy...
October 2016: Lancet
https://www.readbyqxmd.com/read/27966988/docetaxel-loaded-plga-nanoparticles-improve-efficacy-in-taxane-resistant-triple-negative-breast-cancer
#16
Charles J Bowerman, James D Byrne, Kevin S Chu, Allison N Schorzman, Amanda W Keeler, Candice A Sherwood, Jillian L Perry, James C Luft, David B Darr, Allison M Deal, Mary E Napier, William C Zamboni, Norman E Sharpless, Charles M Perou, Joseph M DeSimone
Novel treatment strategies, including nanomedicine, are needed for improving management of triple-negative breast cancer. Patients with triple-negative breast cancer, when considered as a group, have a worse outcome after chemotherapy than patients with breast cancers of other subtypes, a finding that reflects the intrinsically adverse prognosis associated with the disease. The aim of this study was to improve the efficacy of docetaxel by incorporation into a novel nanoparticle platform for the treatment of taxane-resistant triple-negative breast cancer...
December 22, 2016: Nano Letters
https://www.readbyqxmd.com/read/27940304/the-structure-of-polymer-carriers-controls-the-efficacy-of-the-experimental-combination-treatment-of-tumors-with-hpma-copolymer-conjugates-carrying-doxorubicin-and-docetaxel
#17
Milada Šírová, Jiří Strohalm, Petr Chytil, Ondřej Lidický, Jakub Tomala, Blanka Říhová, Tomáš Etrych
The tumor-specific targeting of cancerostatics using polymer drug carriers represents a potential strategy to achieve an effective treatment with reduced side toxicity. Synthetic water-soluble copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) are carriers with tunable architecture and drug loading, tumor-specific accumulation of the drug, and its controlled release. We describe a combination treatment of murine EL4 T cell lymphoma with HPMA-based star conjugates (Mw 250,000gmol(-1)) of doxorubicin (Dox) or docetaxel (Dtx) designed for enhanced tumor accumulation and combination therapy...
December 6, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27934917/co-delivery-of-docetaxel-and-palmitoyl-ascorbate-by-liposome-for-enhanced-synergistic-antitumor-efficacy
#18
Junxiu Li, Chaorui Guo, Fan Feng, Ali Fan, Yu Dai, Ning Li, Di Zhao, Xijing Chen, Yang Lu
Palmitoyl ascorbate (PA) as an antioxidant has the potential for the treatment of cancer. In the present study, a nanocarrier system was developed for co-delivery of docetaxel (DOC) with palmitoyl ascorbate and the therapeutic efficacy of a combination drug regimen was investigated. For this purpose, different ratios of docetaxel and palmitoyl ascorbate were co-encapsulated in a liposome and they all showed high encapsulation efficiency. The average diameters of the liposomes ranged from 140 to 170 nm. Negative zeta potential values were observed for all systems, ranged from -40 mV to -56 mV...
December 9, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27931230/feasibility-and-efficacy-of-gemcitabine-and-docetaxel-combination-chemotherapy-for-bone-and-soft-tissue-sarcomas-multi-institutional-retrospective-analysis-of-134-patients
#19
Kazuhiro Tanaka, Susumu Joyama, Hirokazu Chuman, Hiroaki Hiraga, Hideo Morioka, Hideki Yoshikawa, Masami Hosaka, Mitsuru Takahashi, Tadahiko Kubo, Hiroshi Hatano, Mitsunori Kaya, Junya Toguchida, Yoshihiro Nishida, Akihito Nagano, Hiroshi Tsumura, Yukihide Iwamoto
BACKGROUND: Bone and soft tissue sarcomas (BSTS) are rare malignant tumors. Recently, the combination of gemcitabine and docetaxel (GD) was shown to have activity as second-line setting in BSTS. However, the efficacy as first-line and adjuvant settings and precise profiles of adverse events in Japanese patients are not known yet. In the present study, the feasibility and efficacy of GD in patients with BSTS were investigated. METHODS: Patients with BSTS treated with GD in our institutions were retrospectively analyzed...
December 8, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27916908/epidermal-growth-factor-receptor-status-in-circulating-tumor-cells-as-a-predictive-biomarker-of-sensitivity-in-castration-resistant-prostate-cancer-patients-treated-with-docetaxel-chemotherapy
#20
Takatsugu Okegawa, Naoshi Itaya, Hidehiko Hara, Mitsuhiro Tambo, Kikuo Nutahara
OBJECTIVE: We examined whether epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) can be used to predict survival in a population of bone-metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel chemotherapy. METHODS: All patients with mCRPC who had experienced treatment failure with androgen-deprivation therapy and had received docetaxel chemotherapy were eligible. CTCs and EGFR expression in CTCs were enumerated with the CellSearch System in whole blood...
November 30, 2016: International Journal of Molecular Sciences
keyword
keyword
58392
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"